DrugPatentWatch Database Preview
Drugs in Development Information for CB-839
Email this page to a colleague
» See Plans and PricingWhat is the development status for investigational drug CB-839?
CB-839 is an investigational drug.
There have been 20 clinical trials for CB-839.
The most recent clinical trial was a Phase 1 trial, which was initiated on July 1st 2017.
The most common disease conditions in clinical trials are Carcinoma, Renal Cell, Carcinoma, Non-Small-Cell Lung, and Carcinoma. The leading clinical trial sponsors are Calithera Biosciences, Inc, National Cancer Institute (NCI), and Case Comprehensive Cancer Center.
There are nine US patents protecting this investigational drug and one hundred and seven international patents.
Summary for CB-839
| US Patents | 9 |
| International Patents | 107 |
| US Patent Applications | 24 |
| WIPO Patent Applications | 18 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 1 (2017-07-01) |
| Vendors | 43 |
Recent Clinical Trials for CB-839
| Title | Sponsor | Phase |
|---|---|---|
| A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC | Calithera Biosciences, Inc | Phase 2 |
| Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer | National Cancer Institute (NCI) | Phase 1 |
| CB-839 in Combination With Niraparib in Platinum Resistant Breast Cancer (BRCA) -Wild-type Ovarian Cancer Patients | University of Alabama at Birmingham | Phase 1 |
Clinical Trial Summary for CB-839
Top disease conditions for CB-839
Top clinical trial sponsors for CB-839
US Patents for CB-839
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| CB-839 | Start Trial | Combination therapy with glutaminase inhibitors | Calithera Biosciences, Inc. (South San Francisco, CA) | Start Trial |
| CB-839 | Start Trial | Compositions and methods of treating cancer harboring PIKC3A mutations | Case Western Reserve University (Cleveland, OH) | Start Trial |
| CB-839 | Start Trial | Combination therapy with glutaminase inhibitors and immuno-oncology agents | Calithera Biosciences, Inc. (South San Francisco, CA) | Start Trial |
| CB-839 | Start Trial | Combination therapy with glutaminase inhibitors | Calithera Biosciences, Inc. (South San Francisco, CA) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for CB-839
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| CB-839 | China | 109982703 | 2036-08-25 | Start Trial |
| CB-839 | European Patent Office | 3503893 | 2036-08-25 | Start Trial |
| CB-839 | Japan | 2019524852 | 2036-08-25 | Start Trial |
| CB-839 | World Intellectual Property Organization (WIPO) | 2018039441 | 2036-08-25 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
